Manganese for Blood Sugar and Glucose Metabolism

Manganese sits at the metabolic crossroads of glucose homeostasis. Two of the body's most important gluconeogenic enzymes — pyruvate carboxylase (the first committed step of gluconeogenesis) and phosphoenolpyruvate carboxykinase (PEPCK) — are manganese-dependent. Experimental manganese deficiency in rodents and case reports in humans produce measurable abnormalities in glucose tolerance and insulin response. Epidemiologic studies have found U-shaped associations between dietary manganese and type 2 diabetes risk — both low and high intake increase risk, with the lowest risk in mid-range intake. Manganese also interacts with magnesium in glucose homeostasis: both minerals share transport routes, both are required for ATP-magnesium complex function in glucose phosphorylation, and combined deficiency produces synergistic dysregulation. While manganese is not a treatment for diabetes, adequate manganese status is one of the foundational nutritional requirements for normal glucose metabolism.

Table of Contents

1. Why Glucose Metabolism Needs Manganese
2. Pyruvate Carboxylase: The Gluconeogenic Entry Point
3. Phosphoenolpyruvate Carboxykinase (PEPCK)
4. TCA Cycle Anaplerosis and Glucose-Alanine Cycling
5. Manganese Deficiency and Impaired Insulin Response
6. Glucose Tolerance: Human Studies and Animal Models
7. The Manganese-Magnesium Interplay in Glucose Homeostasis
8. Type 2 Diabetes: U-Shaped Risk Curve
9. MnSOD and Diabetic Complications
10. Clinical Takeaways for Patients with Glycemic Dysregulation
11. Key Research Papers
12. Connections

Why Glucose Metabolism Needs Manganese

Glucose homeostasis is the body's most carefully regulated metabolic parameter. Plasma glucose must be maintained within a narrow range (approximately 70-110 mg/dL in the fasting state) because both hypoglycemia (impaired brain function) and hyperglycemia (vascular and tissue damage) are immediately dangerous. The regulatory system has three principal components: dietary glucose absorption, hepatic glucose production (gluconeogenesis and glycogenolysis), and peripheral glucose uptake (especially by muscle and adipose tissue under insulin control).

Manganese is critical at two specific points in this system:

1. Hepatic glucose production via gluconeogenesis — the synthesis of new glucose from non-carbohydrate precursors (lactate, amino acids, glycerol) during fasting, prolonged exercise, or low-carbohydrate states. Two of the four uniquely gluconeogenic enzymes — pyruvate carboxylase and PEPCK — require manganese.
2. TCA cycle anaplerosis — replenishment of TCA cycle intermediates that are drawn off for biosynthesis. Pyruvate carboxylase is the principal anaplerotic enzyme, generating oxaloacetate from pyruvate.

The integration of these two roles places manganese directly in the path of glucose-handling in fasting metabolism. Inadequate manganese status compromises both gluconeogenesis (impaired generation of new glucose when needed) and TCA cycle function (impaired oxidative ATP production from carbohydrate, fat, and protein substrates).

Back to Table of Contents

Pyruvate Carboxylase: The Gluconeogenic Entry Point

Pyruvate carboxylase (PC, EC 6.4.1.1) catalyzes the ATP-dependent carboxylation of pyruvate to oxaloacetate:

Pyruvate + CO2 + ATP → Oxaloacetate + ADP + Pi

This is the first committed step of gluconeogenesis from pyruvate or lactate, and it is also the principal anaplerotic reaction that replenishes oxaloacetate for TCA cycle function. The enzyme is a biotin-dependent carboxylase with a complex active-site architecture that includes both a biotin cofactor and a manganese ion (or, in some species and tissues, magnesium — the two divalent metals can substitute to some extent, but manganese has higher catalytic efficiency).

• Tissue distribution — PC is highly expressed in liver, kidney cortex, and adipose tissue (where it supports fatty acid synthesis by providing oxaloacetate for citrate export from mitochondria). The liver and renal cortex are the principal sites of physiologic gluconeogenesis.
• Regulation — PC is allosterically activated by acetyl-CoA. This creates an elegant control logic: when fatty acid oxidation is high (generating abundant acetyl-CoA), PC is activated to generate oxaloacetate, which the liver uses for gluconeogenesis during the fasting state.
• Inherited PC deficiency — a rare autosomal recessive disorder causing severe lactic acidosis, hypoglycemia, hyperammonemia, and severe neurological impairment. The phenotype demonstrates how dependent the body is on this single enzyme for both glucose synthesis and TCA cycle integrity.
• Manganese vs magnesium at the active site — in vitro, both metals can support catalysis. In vivo, the strict requirement for manganese has been debated, with some authors arguing the enzyme is functionally a magnesium-enzyme in mammals. However, manganese deficiency consistently reduces PC activity in animal models, suggesting that even if magnesium can substitute, manganese is the preferred and physiologically dominant cofactor.

Back to Table of Contents

Phosphoenolpyruvate Carboxykinase (PEPCK)

PEPCK (EC 4.1.1.32) is the second committed enzyme of gluconeogenesis. It catalyzes the GTP-dependent decarboxylation and phosphorylation of oxaloacetate to phosphoenolpyruvate (PEP):

Oxaloacetate + GTP → PEP + CO2 + GDP

This reaction effectively reverses the pyruvate kinase step of glycolysis (which generates pyruvate from PEP). The combined PC + PEPCK pathway converts pyruvate to PEP, bypassing the irreversible pyruvate kinase reaction and committing carbon to the gluconeogenic direction.

• Manganese cofactor — PEPCK is strictly metal-dependent for activity, with manganese as the highest-activity cofactor. Magnesium can substitute with reduced efficiency. The metal participates in the GTP-mediated phosphoryl transfer chemistry.
• Cytosolic vs mitochondrial isoforms — humans express two PEPCK genes: PCK1 (cytosolic, PEPCK-C) and PCK2 (mitochondrial, PEPCK-M). Both are manganese-dependent and both contribute to gluconeogenesis in different proportions in different tissues. PEPCK-C dominates in liver and kidney; PEPCK-M has been increasingly recognized as important in many cancers and in islet beta-cell function.
• Transcriptional regulation — PEPCK-C transcription is upregulated by glucagon, cortisol, and starvation, and downregulated by insulin and feeding. This transcriptional control is part of how insulin suppresses hepatic glucose output. Resistance to this suppression (insulin resistance in type 2 diabetes) leads to inappropriately high hepatic gluconeogenesis even in the fed state — one of the central pathologies of the disease.
• Therapeutic target — metformin (the first-line type 2 diabetes drug) reduces hepatic glucose output in part by inhibiting mitochondrial gluconeogenic flux, which has effects on PEPCK function. The fact that the most successful diabetes drug works in part through this pathway underscores its physiologic importance.

Back to Table of Contents

TCA Cycle Anaplerosis and Glucose-Alanine Cycling

The tricarboxylic acid (TCA) cycle generates NADH and FADH2 for the electron transport chain and supplies precursors for biosynthesis: alpha-ketoglutarate for amino acid synthesis, succinyl-CoA for heme synthesis, oxaloacetate for gluconeogenesis and aspartate synthesis. When TCA intermediates are drawn off for biosynthesis (cataplerosis), they must be replaced (anaplerosis) or the cycle will run down.

Pyruvate carboxylase is the dominant anaplerotic enzyme in most mammalian tissues. Inadequate manganese reduces PC activity, slows anaplerosis, and gradually depletes TCA cycle intermediates. The result is reduced oxidative ATP production from all substrates (glucose, fatty acids, amino acids) and increased reliance on glycolytic (anaerobic) ATP production with lactate accumulation. This metabolic shift mimics in miniature what happens in more severe mitochondrial disorders.

The glucose-alanine cycle is one specific case where manganese's role is particularly visible. Working muscle generates alanine (from pyruvate by transamination with glutamate), which is exported to the liver. In the liver, alanine is converted back to pyruvate (with the amino group destined for the urea cycle, which itself requires manganese-containing arginase). Pyruvate then enters gluconeogenesis via manganese-dependent PC and PEPCK to regenerate glucose, which returns to the muscle. Manganese is required at two steps of this cycle (arginase in urea synthesis, PC and PEPCK in gluconeogenesis) plus one nitrogen-disposal step (glutamine synthetase in skeletal muscle for ammonia handling).

Back to Table of Contents

Manganese Deficiency and Impaired Insulin Response

Both classical experimental manganese deficiency studies (rodents, guinea pigs) and rarer human case reports demonstrate that manganese deprivation impairs glucose handling and the insulin response:

• Hambidge human case (1979) — an adult man inadvertently maintained on a manganese-free experimental diet for several months developed glucose intolerance, decreased body weight, transient dermatitis, and a vitamin K-responsive coagulopathy. Glucose tolerance normalized when manganese was reintroduced. This case is the closest thing to a controlled human deficiency experiment.
• Rodent oral glucose tolerance studies — manganese-deficient rats consistently show flattened insulin response curves and elevated post-load glucose. The defect is partially reversible with manganese repletion within days to weeks.
• Islet beta-cell function — pancreatic beta cells express both MnSOD and the gluconeogenic enzymes that are manganese-dependent. Reduced manganese availability impairs glucose-stimulated insulin secretion in vitro, possibly through effects on intracellular ATP production and the K-ATP channel mechanism that triggers insulin release.
• Insulin signaling and oxidative stress — oxidative stress contributes to insulin resistance through multiple mechanisms (serine phosphorylation of IRS-1, JNK activation, NF-kB activation). Reduced MnSOD activity, by allowing greater mitochondrial oxidative stress, may indirectly worsen insulin sensitivity.
• Hepatic insulin signaling — the liver's response to insulin involves suppression of gluconeogenic gene expression (FOXO1, PEPCK, glucose-6-phosphatase). The transcriptional response is normal in manganese deficiency, but the impact on the metabolic flux is altered because the enzymes are partially inactive at the protein level.

Back to Table of Contents

Glucose Tolerance: Human Studies and Animal Models

The human glucose-tolerance literature on manganese is limited but reasonably consistent:

• Walter et al. (1991) — reported lower whole-blood manganese in patients with newly diagnosed type 2 diabetes compared with non-diabetic controls. Several subsequent observational studies have replicated this finding, while others have not, suggesting the effect is modest and study-design-sensitive.
• Koh et al. (2014) — in a large Korean cohort, lower serum manganese was associated with higher fasting glucose and higher prevalence of diabetes. The lowest-quintile group had approximately 1.5-fold higher diabetes prevalence than the middle quintile.
• Du et al. (2020) — meta-analysis of 12 studies found that low serum manganese was associated with increased risk of type 2 diabetes, while high serum manganese (above the upper-quartile cutoff) was also associated with increased risk — the U-shaped relationship discussed below.
• Animal studies — consistently show that manganese-deficient animals have impaired glucose tolerance and reduced insulin response. The defect appears at multiple points: reduced beta-cell insulin secretion, impaired peripheral glucose uptake, and dysregulated hepatic glucose output.
• Manganese repletion in deficient individuals — restoration of normal dietary manganese normalizes glucose handling in deficient animals and in the rare deficient human cases. Manganese supplementation in already-replete individuals has not demonstrated additional glucose-handling benefit and is not recommended for that purpose.

Back to Table of Contents

The Manganese-Magnesium Interplay in Glucose Homeostasis

Magnesium and manganese have overlapping roles in glucose metabolism, and their statuses are nutritionally interrelated. Understanding the interplay helps clarify why neither mineral acts in isolation.

• Shared substrate, partial substitution — many enzymes that use one divalent metal will accept the other with reduced efficiency. Pyruvate carboxylase, PEPCK, and most kinases that nominally use Mg-ATP can use Mn-ATP. In tissues with adequate manganese, partial substitution at magnesium-preferring enzymes may explain some clinical signals.
• Glucose phosphorylation — hexokinase and glucokinase use Mg-ATP as substrate (more accurately, the magnesium-ATP complex). Magnesium is rate-limiting; manganese substitution is possible but slower.
• Insulin receptor tyrosine kinase — the insulin receptor's intracellular tyrosine kinase activity is magnesium-dependent. Low intracellular magnesium impairs insulin signal transduction and contributes to insulin resistance.
• Combined deficiency — in chronic conditions associated with combined magnesium and manganese deficiency (chronic alcoholism, severe protein-calorie malnutrition, post-bariatric surgery), the impact on glucose homeostasis exceeds what either deficiency alone would produce.
• Transport competition — divalent metal transporter 1 (DMT1) handles iron, manganese, and other divalent cations. High iron supplementation can reduce manganese uptake and indirectly affect magnesium-manganese balance. The ZIP14 transporter handles manganese, zinc, and iron. The overlapping transport network means trace-mineral status is best assessed as a panel rather than as individual minerals.
• Practical implication — for patients with glycemic dysregulation, ensuring adequate magnesium intake (300-400 mg/day) is more strongly evidence-supported than manganese supplementation. Manganese should be adequate but not aggressively supplemented; magnesium can be safely supplemented to higher levels.

For more on magnesium and glucose metabolism, see the Magnesium page.

Back to Table of Contents

Type 2 Diabetes: U-Shaped Risk Curve

One of the more interesting findings in nutritional epidemiology of manganese is the U-shaped relationship between manganese intake (or blood manganese) and type 2 diabetes risk. Both very low and very high manganese have been associated with elevated diabetes risk:

• Low manganese — impaired gluconeogenic enzyme function, reduced beta-cell capacity, increased oxidative stress in beta cells and peripheral tissues
• High manganese — possibly pro-oxidant effects of free manganese, manganese-induced mitochondrial dysfunction, displacement of magnesium and other divalent metals from regulatory sites, oxidative stress paradoxes at very high concentrations
• Optimum range — the lowest diabetes risk in epidemiologic studies generally corresponds to dietary intake in the 2-4 mg/day range and serum manganese in the middle population quartiles, well within the AI range and well below the UL of 11 mg/day

The practical implication is to stay within the recommended intake range from food sources, where the U-shaped curve is most clearly mitigated. High-dose supplementation is not warranted and may be counterproductive. Patients consuming a varied diet with whole grains, nuts, legumes, leafy greens, and tea typically achieve optimal manganese intake without supplementation.

The U-shape also has an environmental-exposure component — populations with high environmental manganese (well water above EPA limits, certain industrial regions) may have elevated diabetes risk that masquerades as a "high-intake" effect but is really an inhalational or non-physiologic exposure problem.

Back to Table of Contents

MnSOD and Diabetic Complications

Once type 2 diabetes is established, mitochondrial superoxide overproduction in target tissues (vascular endothelium, retinal capillaries, renal tubular cells, peripheral nerves) is the upstream driver of the major chronic complications. The Brownlee unifying hypothesis places mitochondrial superoxide at the apex of the complication cascade:

1. Hyperglycemia accelerates flux through the electron transport chain in target tissues
2. Excess electron flow generates excess superoxide at complexes I and III
3. If MnSOD capacity is exceeded, superoxide accumulates
4. Superoxide activates four damaging downstream pathways (polyol, hexosamine, PKC, advanced glycation end-product formation)
5. The four pathways converge on vascular and neuronal damage manifesting as nephropathy, retinopathy, neuropathy, and accelerated atherosclerosis

MnSOD adequacy is therefore upstream of the entire complication cascade. The SOD2 Val16Ala polymorphism (discussed in detail on the antioxidant MnSOD deep-dive) modulates this: Ala/Ala genotype carriers have approximately 30-40% lower MnSOD activity and meaningfully higher risk of diabetic nephropathy and retinopathy at any given level of glycemic control. Adequate manganese intake (along with the broader mitochondrial-antioxidant support strategy) should be part of comprehensive diabetic-complication prevention, particularly for Ala/Ala genotype carriers.

This does not mean manganese supplementation prevents diabetic complications — the evidence does not support that claim. It means manganese adequacy is one of multiple inputs to a system that, when working well, buffers the diabetic state and slows complication onset.

Back to Table of Contents

Clinical Takeaways for Patients with Glycemic Dysregulation

• Ensure dietary adequacy — 1.8-2.3 mg/day from food sources. Whole grains, nuts, legumes, leafy greens, tea, and pineapple are the major contributors. A varied diet supplies this without difficulty.
• Avoid aggressive supplementation — the U-shaped risk curve means more is not better. Stay within 2-5 mg/day from supplements (if any), and well below the 11 mg/day UL from all sources combined.
• Prioritize magnesium — for glycemic dysregulation specifically, magnesium has a stronger evidence base than manganese. 300-400 mg/day of magnesium (from food and/or supplement) improves insulin sensitivity in deficient individuals. Magnesium glycinate or magnesium malate are well-tolerated forms.
• Address the broader nutritional picture — zinc, chromium, biotin, vitamin D, omega-3 fatty acids, B vitamins (especially thiamine, B6, folate, B12) all have roles in glucose metabolism. Single-mineral approaches are less effective than comprehensive nutritional optimization.
• Lifestyle remains primary — even with optimal micronutrient status, glycemic dysregulation in the type 2 diabetes spectrum responds primarily to dietary carbohydrate moderation, regular aerobic and resistance exercise, adequate sleep, stress management, and weight management. Micronutrient support is adjunctive, not curative.
• Special populations — patients with chronic alcoholism, post-bariatric surgery, inflammatory bowel disease, celiac disease, and long-term parenteral nutrition are at risk of multi-mineral deficiency including manganese. Comprehensive trace-mineral assessment and repletion is part of standard management.
• Liver disease caution — patients with cirrhosis or biliary obstruction cannot excrete manganese normally and are at risk of CNS accumulation. Avoid supplementation; rely on dietary intake alone.

This content is provided for informational purposes only and does not constitute medical advice. Patients with diabetes or glucose intolerance should be managed by appropriate medical professionals; nutritional optimization is one component of comprehensive care.

Back to Table of Contents

Key Research Papers

1. Hambidge KM, Casey CE, Krebs NF (1986). Zinc and other trace elements. In: Trace Elements in Human and Animal Nutrition. (Includes the inadvertent-deficiency human case.) — PubMed
2. Brownlee M (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615-1625. — PubMed
3. Koh ES et al. (2014). Serum manganese concentration is associated with risk of metabolic syndrome and type 2 diabetes mellitus in Korean adults. Biological Trace Element Research. — PubMed
4. Du S et al. (2020). Association between blood manganese and type 2 diabetes mellitus: a meta-analysis. Journal of Trace Elements in Medicine and Biology. — PubMed
5. Jomova K, Valko M (2011). Advances in metal-induced oxidative stress and human disease. Toxicology 283(2-3):65-87. — PubMed
6. Burch HB et al. (1975). Hereditary pyruvate carboxylase deficiency: leigh-like syndrome and metabolic acidosis. Journal of Pediatrics. — PubMed
7. Yang BY et al. (2020). Association of dietary manganese intake with diabetes and prediabetes among Chinese adults. Frontiers in Nutrition. — PubMed
8. Liu L et al. (2017). Blood and urinary manganese in relation to type 2 diabetes among Chinese adults. Journal of Diabetes. — PubMed
9. Hassel B et al. (2016). Glutamate uptake is changed in the brain of glutamine synthetase deficient mice. Journal of Neurochemistry (mechanistic context for manganese glutamine synthetase). — PubMed
10. Walter RM et al. (1991). Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 14(11):1050-1056. — PubMed
11. Burrage LC et al. (2014). Disorders of branched chain amino acid metabolism: from rare leucine, isoleucine, and valine cycles to MSUD treatment paradigms. Human Molecular Genetics. — PubMed
12. Rorsman P, Ashcroft FM (2018). Pancreatic beta-cell electrical activity and insulin secretion: of mice and men. Physiological Reviews 98(1):117-214. — PubMed

PubMed Topic Searches

• PubMed: Pyruvate carboxylase + manganese
• PubMed: PEPCK + manganese
• PubMed: Manganese + glucose tolerance
• PubMed: Manganese + T2DM epidemiology
• PubMed: Magnesium + manganese + glucose

Back to Table of Contents

Connections

• Manganese Overview
• Manganese Benefits Hub
• Manganese for Bone Formation
• Manganese MnSOD Antioxidant
• Manganese for Wound Healing
• Magnesium
• Chromium
• Zinc
• Vitamin D3
• Type 2 Diabetes
• Metabolic Syndrome
• Obesity
• Insulin Resistance
• Oxidative Stress
• Brown Rice
• Spinach
• Cinnamon
• All Minerals

Back to Table of Contents